potential COVID-19 treatments living meta-analysis of clinical studies

demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only

74 studies excluded by filtering options 0

4909	Lee, 2004	0	1	0	selection pending
4910	Soo, 2004	0	0	0	selection pending
4911	HKU/UCH SARS Study Group, 2004	0	0	0	selection pending
4912	Chan, 2003	0	0	0	selection pending
4913	Beigel, 2018	0	1	0	selection pending
5092	Yang, 2020	1	13	3		not a RCT	high risk of bias
5228	Bean, 2020	1	19	3		not a RCT	high risk of bias
5295	Zhang, 2020	1	13	3		not a RCT	high risk of bias
5331	Li, 2020	1	13	4		not a RCT	high risk of bias
5332	Meng, 2020	1	13	4		not a RCT	high risk of bias
5345	Yan et al., 2020	1	20	4		not a RCT	high risk of bias
5346	Mancia, 2020	1	20	3		not a RCT	high risk of bias
5347	Mehra, 2020	2	12	4	excluded	not a RCT	high risk of bias
5348	Reynolds (COVID positive patient), 2020	1	13	3		not a RCT	high risk of bias
5349	Reynolds (prophylaxis), 2020	1	13	3		not a RCT	high risk of bias
5370	Khera (outpatients), 2020	1	13	3		not a RCT	high risk of bias
5372	Khera (inpatients), 2020	1	13	3		not a RCT	high risk of bias
5399	Northwell Consortium (Richardson), 2020	0	99	0	selection pending
5440	Morales, 2020	1	13	0		not a RCT	risk of bias not avaialble
5442	Mancia, 2020	0	0	0	selection pending
5521	Del Amo, 2020	2	0	0	excluded		risk of bias not avaialble
5532	Fosbøl, 2020	0	0	0	selection pending
5604	Schneeweiss, 0	0	13	0	selection pending
5605	Vila-Corcole, 0	0	13	0	selection pending
5619	Pan, 2020	0	13	0	selection pending
5629	Fosbol, 2020	0	0	0	selection pending
5797	Rossi, 0	0	13	0	selection pending
5903	Anzola, 2020	0	10	0	selection pending
6660	Bae, 2021	0	12	0	selection pending
6729	Shah, 2021	1	13	3		not a RCT	high risk of bias
6788	Waissengrin, 2021	0	13	0	selection pending
6790	Pawlowski, 2021	1	13	0		not a RCT	risk of bias not avaialble
6857	Anderson, 2020	0	0	0	selection pending
6894	Andrejko, 2021	1	20	0		not a RCT	risk of bias not avaialble
6927	Rossman, 2021	0	13	0	selection pending
6931	Yair, 2921	1	32	0		not a RCT	risk of bias not avaialble
6934	Boyarsky, 2021	1	32	0		not a RCT	risk of bias not avaialble
6949	Pawlowski, 2021	1	13	0		not a RCT	risk of bias not avaialble
6981	Public Health England (Harris), 2021	1	13	3		not a RCT	high risk of bias
7025	Haberman, 2021	0	13	0	selection pending
7055	Shroff, 2021	0	0	0	selection pending
7070	PHE variants (Technical briefing 12 22 may 2021), 2021	2	20	2	excluded	not a RCT
7325	Skowronski, 2021	0	13	0	selection pending
7419	Scotland delta (Sheikh), 2021	1	20	3		not a RCT	high risk of bias
7420	PHE (Stowe), 2021	2	13	3	excluded	not a RCT	high risk of bias
7940	Wall, 2021	0	0	0	selection pending
7950	Harris, 2021	1	13	3		not a RCT	high risk of bias
8143	Butt, 2021	1	20	2		not a RCT
8147	Canada (Nasreen), 2021	1	20	2		not a RCT
8149	PHE Technical briefing 16 (11/18 June 2021), 2021	2	13	3	excluded	not a RCT	high risk of bias
8150	Ramasamy, 2021	0	32	0	selection pending
8163	Israel delta press release, 0	1	0	0			risk of bias not avaialble
8164	Public Health England, May 16, 2021 (Bernal), 2021	1	20	2		not a RCT
8255	REACT-SCOT, 2021	1	20	0		not a RCT	risk of bias not avaialble
8272	Martinez-Baz, 2021	1	13	0		not a RCT	risk of bias not avaialble
8274	REACT-1 round 13 final report (Elliott, Imperial College London), 2021	1	13	3		not a RCT	high risk of bias
8275	Musser, 2021	2	13	0	excluded	not a RCT	risk of bias not avaialble
8294	CDC Mesa County, Colorado, 2021	1	13	3		not a RCT	high risk of bias
8313	Bahl (Fully vaccinated vs unvaccinated), 2021	0	10	0	selection pending
8350	Rosenberg, 2021	2	13	0	excluded	not a RCT	risk of bias not avaialble
8359	Oxford (Pouwels), 2021	1	13	2		not a RCT
8360	HEROES-RECOVER (Fowlkes), 2021	1	13	3		not a RCT	high risk of bias
8513	Grannis, 2021	1	20	3		not a RCT	high risk of bias
8514	VA (Bajema), 2021	1	20	3		not a RCT	high risk of bias
8515	Scobie, 2021	2	20	0	excluded	not a RCT	risk of bias not avaialble
9170	UKHSA report 33 (23 december 2021), 2021	2	20	0	excluded	not a RCT	risk of bias not avaialble
9176	UKHSA 31 december 2021, 2021	2	20	0	excluded	not a RCT	risk of bias not avaialble
9214	Southern California (Lewnard), 2022	2	13	0	excluded	not a RCT	risk of bias not avaialble
9216	Sultan, 2022	0	12	0	selection pending
9224	Reynolds, 2022	0	0	0	selection pending
9267	Ostropolets, 2021	0	12	0	selection pending
9294	UKHSA (report W4- 27 January), 2022	2	12	0	excluded	not a RCT	risk of bias not avaialble
9491	Li X, 2022	1	12	0		not a RCT	risk of bias not avaialble
9590	UKHSA report week 12 (24 March 2022), 2022	1	12	0		not a RCT	risk of bias not avaialble

	COVID 19 hospitalized
	COVID 19 all comers
potential COVID-19 treatments
anti-inflammatoty and immuno-therapy
Immunostimulants drugs
convalescent plasma treatment	LIFESAVER
Immunosuppressants drugs
anti-interleukin-6
tocilizumab	BACC Bay Tocilizumab Trial
janus kinase (JAK) inhibitor
baricitinib	RECOVERY
leflunomide	Wang
antiviral and associated therapy
chloroquine and derivatives
hydroxychloroquine	NOR-Solidarity ...
favipiravir	Chang Chen et al. NCT04310228-FAVI ... Lou ...
remdesivir	Norwegian NOR study ... Andreas ...
umifenovir (arbidol)	ELACOI ...
miscellaneous
camostat mesilate	Gunst JD
Renin-angiotensin-system-acting agents
angiotensin receptor blockers (ARBs)
losartan	University of Minnesota